Lipocine
LPCN
29 hedge funds and large institutions have $10.1M invested in Lipocine in 2020 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 3 reducing their positions, and 10 closing their positions.
330% more call options, than puts
Call options by funds: $902K | Put options by funds: $210K
267% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 3
86% more capital invested
Capital invested by funds: $5.42M → $10.1M (+$4.64M)
0.11% more ownership
Funds ownership: 0.53% → 0.64% (+0.11%)
12% less funds holding
Funds holding: 33 → 29 (-4)
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.9M |
| 2 |
BlackRock
New York
|
+$1.39M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$670K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$395K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$157K |
Top Sellers
LPCN Hedge Fund Activity: Q3 2020 in Review
29 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q3 2020, worth a combined $10.1M — up 86% from $5.42M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of LPCN and 6 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 11 added.
The largest buyer was Vanguard Group, adding an estimated $2.9M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $398K sold.
- 29 institutional investors held Lipocine (LPCN) as of Q3 2020, down from 33 in Q2 2020.
- Funds reported $10.1M of Lipocine stock for Q3 2020, up 86% quarter-over-quarter.
- 6 funds opened new Lipocine positions in Q3 2020 and 10 closed out, a net change of -4 holders.
- The largest Lipocine buyer in Q3 2020 was Vanguard Group, an estimated $2.9M added.
- The largest Lipocine seller in Q3 2020 was Renaissance Technologies, an estimated $398K sold.
Based on aggregated 13F filings for Q3 2020.